Figure 2.

Sensitization of melanoma cells for death ligand-induced apoptosis. (a) Apoptosis (sub-G1 populations) and cytotoxicity (LDH release) were determined in melanoma cell lines in response to treatment with 2–5 μM BMS-345541±TRAIL (20 ng/ml). (b) Examples of cell cycle analyses are shown. BMS-345541/TRAIL-treated cells (open graphs) were compared with DMSO treated controls (filled graphs). (c) Apoptosis (sub-G1 cells) and cytotoxicity (LDH release) are shown in Mel-HO and A-375 in response to BMS-345541 (5 μM) ±CH-11 (50 ng/ml). (d) Photographs of bisbenzimide-stained A-375 and A-375-TS cells treated for 24 h with BMS-345541/TRAIL. (e) Quantitative evaluations of proportions of cells with fragmented nuclei or condensed chromatin are shown. (f) Real-time cell analyses (xCELLigence) of melanoma cell lines treated with TRAIL (20 ng/ml, TR), BMS-345541 (2 μM, BM) or the combination (T/B) were compared with control cells (Co). (a, c, e, f) Means and S.D.'s of triplicate values of representative experiments are shown. All experiments were performed at least two times, which revealed highly comparable results. Statistical significance is indicated (*P<0.05), comparing the combination treatment with BMS-345541 alone